about
Eating disorders in schizophrenia: implications for research and managementPharmacology of hallucinations: several mechanisms for one single symptom?The myth of schizophrenia as a progressive brain diseaseYoga as part of a package of care versus standard care for schizophreniaAcetylsalicylic acid (aspirin) for schizophreniaYoga versus standard care for schizophreniaYoga versus non-standard care for schizophreniaBifeprunox versus placebo for schizophreniaTai chi for schizophreniaZuclopenthixol versus placebo for schizophreniaFlupenthixol versus placebo for schizophreniaZuclopenthixol versus placebo for schizophreniaYoga for schizophreniaFlupenthixol versus placebo for schizophreniaCognitive behaviour therapy (group) for schizophreniaClozapine versus other atypical antipsychotics for schizophreniaEfficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysisCelecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On TrialsA New Perspective on Delusional States - Evidence for Claustrum Involvement."No more a child, not yet an adult": studying social cognition in adolescencePreclinical models of antipsychotic drug action.Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates TreatmentYoga for schizophrenia: a systematic review and meta-analysisCurious cases: Acromegaly and schizophrenia: an incidental association?Gesture Performance in Schizophrenia Predicts Functional Outcome After 6 Months.Gene × Environment Interactions in Schizophrenia: Evidence from Genetic Mouse ModelsPostmortem evidence of cerebral inflammation in schizophrenia: a systematic reviewMaking Sense of: Sensitization in SchizophreniaMagnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future researchChanges in neurocognitive functioning during transition to manifest disease: comparison of individuals at risk for schizophrenic and bipolar affective psychosesThe ameliorating effects of 5,7-dihydroxy-6-methoxy-2(4-phenoxyphenyl)-4H-chromene-4-one, an oroxylin A derivative, against memory impairment and sensorimotor gating deficit in miceRepetitive transcranial magnetic stimulation (rTMS) for treating major depression and schizophrenia: a systematic review of recent meta-analysesSchizophrenia is associated with dysregulation of a Cdk5 activator that regulates synaptic protein expression and cognition.The Psychosis Recent Onset GRoningen Survey (PROGR-S): defining dimensions and improving outcomes in early psychosisInvestigation of the genetic association between quantitative measures of psychosis and schizophrenia: a polygenic risk score analysisNeuroanatomical study of the A11 diencephalospinal pathway in the non-human primateMolecular substrates of schizophrenia: homeostatic signaling to connectivityToll-like receptor-2 deficiency induces schizophrenia-like behaviors in miceMechanisms Underlying Auditory Hallucinations-Understanding Perception without Stimulus.Priming of metabolic dysfunctions by prenatal immune activation in mice: relevance to schizophrenia.
P2860
Q21284525-FE96AB57-A1B1-43A2-9575-D8EB12C9FBEFQ21284720-F817689F-D874-46DB-B574-2950FC986883Q24067152-C5A041D8-CDB8-4E03-8B47-F0AE8A4D3BF2Q24185976-163AAABD-B7C4-4AFB-A56D-30D95FAA7AD8Q24186077-1F45DB38-76F3-4882-B8DB-68993CAA21AAQ24186431-37144CA1-6873-4CED-A5E1-171B5FE689BDQ24186727-EF3BB7F4-AA08-4607-B10F-43CCC4C627CAQ24186774-7B42929B-C445-416D-ABC0-7E990B4BD447Q24186914-02062CB1-087E-44F2-82F2-8B7CB009FB14Q24187287-2F01C686-260E-46D4-8C0D-B86A50689366Q24200708-A9C12E6E-900A-4E3B-9530-3829CA363B55Q24202456-A05E28EF-A112-49D3-8BFF-F2C7D19589F4Q24202517-68D3586D-9781-4457-9E1A-429262DF9B78Q24202853-D7EBECE6-1577-4F01-A74C-4F76481D135BQ24203825-9ED66153-F46D-414A-A0B4-11A205652BCCQ24236422-5469AA5D-A29B-4E33-8CA2-B16D0C3FFE47Q24606868-28A900DA-6388-4007-A520-7A4E73F0DD6DQ26741541-45E70894-FD5A-4639-BB68-6D26A9982BB4Q26776159-0D338280-A0B8-4355-9B1F-9FC01094D035Q26782862-F21358B1-A8E0-43F9-8E14-7A4EDA74F80EQ26827502-3CE69007-A5E0-45E2-86E9-6AD7CE7AC939Q27015872-18ACDEE6-0CA8-460F-AADA-0C28C28BB501Q27024081-FBE9ABC1-A8CC-4178-8A60-DD607E6EC138Q27025160-B36371DA-7F19-462D-905F-05ACB5883F6AQ27319903-5AE6CE6F-D4DF-43E2-8EAF-D458C7435753Q28067507-34E9F4C8-D712-40A2-8477-167D32FF157BQ28077391-882DFDE8-2E42-41E9-B3C3-4BF21F382727Q28077939-CA4B8EAB-4A6F-4570-A15F-A854CACDFA9CQ28082090-DF6C4568-7B02-4C13-A155-320DB88C82C8Q28256286-41CD0473-3BD4-4E6F-8262-5B016930F64CQ28288084-06540E7C-4E6A-4428-B27D-FAFE363B11F4Q28290977-F1F55689-ED93-4DBB-994B-19ACE85A877CQ28391148-EB641B91-7BB2-4FB7-B877-4DE11B56419AQ28545094-02DD81AB-B80C-4637-9611-5A99CB61BD78Q28728068-FA0F85ED-61DF-403B-A413-238CF7C58739Q28748883-E94F8DA3-8B73-4ED2-8576-B89B8904B34BQ30383611-0964CA74-C24B-4E4C-B54C-6DE3054EC1CFQ30418233-D5A0707D-608A-45D2-AED3-EBA442DBD841Q30436393-187ED9B1-374B-45EF-ACBE-7475671F9288Q30442468-F2A4BBAB-BEA2-4441-B3B9-2482DBC19355
P2860
description
Disorder curable by (much and ...... en-free diet, amalgam-induced]
@en
article publié dans la revue scientifique The Lancet
@fr
im August 2009 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2009
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Schizophrenia
@en
Schizophrenia
@nl
type
label
Schizophrenia
@en
Schizophrenia
@nl
altLabel
(chronic) (paranoid) (catatonic) S., Psychosis, F 20 ff. diagnostics
@en
prefLabel
Schizophrenia
@en
Schizophrenia
@nl
P1433
P1476
Schizophrenia
@en
P304
P356
10.1016/S0140-6736(09)60995-8
P407
P577
2009-08-01T00:00:00Z